Spotlight on Research

Eight years ago, JDRF created the Artificial Pancreas Project, and through the generosity of our supporters, we have been able to invest more than $98 million to fund artificial pancreas (AP) research and development. Today, this project is spurring innovation and bringing us closer to our goal of creating AP systems that automatically measure blood-glucose […]

T1D Trial Looks to Teach an Old Drug New Tricks

JDRF-funded clinical study of a drug called TUDCA looks to improve beta cell functioning in people recently diagnosed with T1D Until recently, much of type 1 diabetes (T1D) research has focused on suppressing the autoimmune system to prevent or reverse disease, but this approach has been slow to yield promising, long-term results in people with […]

Re-educating the Immune System in T1D

JDRF partner Selecta developed a novel technology for creating a T1D vaccine to potentially halt the disease process It has been more than 30 years since scientists identified the basic autoimmune feature of type 1 diabetes (T1D) when they discovered autoantibodies binding to targets from cells in the pancreas. And yet, devising therapies to halt […]

Unlocking a Combination Therapy for New Onset T1D

A new study is further assessing if a novel combination of drugs could help treat new onset type 1 diabetes University of Florida researchers are ready to launch a new clinical study to examine if a combination of two U.S Food and Drug Administration (FDA) approved drugs, antithymocyte globulin (ATG) and granulocyte colony stimulating factor […]

Advancing a Key Artificial Pancreas Technology

Stable liquid glucagon developed by JDRF partner Xeris evaluated in first clinical study The JDRF Artificial Pancreas (AP) project is focused on accelerating the development of commercially-viable AP systems that better mimic the biological function of the pancreas and reduce the daily burden of managing type 1 diabetes (T1D). To achieve this goal, JDRF funds […]

Improving Beta Cell Health and Survival

JDRF-funded clinical study to test marketed drug to improve beta cell health and survival in T1D JDRF recently awarded a $2.1 million grant to Anath Shalev, M.D., director of the University of Alabama’s (UAB) Comprehensive Diabetes Center, to test the impact of a common blood pressure drug called verapamil on the health and survival of […]

Historic Progress for JDRF Encapsulation Research Program

First people with type 1 diabetes receive experimental encapsulated cell replacement therapies in clinical studies Two JDRF-funded partners have successfully implanted people with type 1 diabetes (T1D) with experimental encapsulated cell replacement therapies in clinical studies. These two programs are running in parallel and are evaluating two distinct encapsulation therapies. Encapsulated cell replacement therapy involves […]

It’s Time to Redefine Type 1 Diabetes

Last month, JDRF co-hosted a workshop where healthcare experts from government, nonprofit agencies and educational institutions discussed expanding the definition of Type 1 Diabetes (T1D) to recognize the earliest stages of human T1D before a person is clinically symptomatic. The benefits of the proposed system could include potentially faster drug development, identification of people living […]

Making the T1D Vaccine a Reality

Nanoparticle-based vaccine is designed to re-educate the immune system and halt the attack on the pancreas Over the last three years, Selecta Bioscience, a clinical stage biotechnology company, has been developing nanoparticles called Synthetic Vaccine Particle (SVP) as an immunotherapy for Type 1 diabetes (T1D) with support from JDRF and it was announced this week […]